Category: Pharmaceuticals

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The rare diseases treatment market has witnessed substantial growth, with its size surging from $169.56 billion in 2023 to $192.22 billion in 2024. This remarkable expansion is attributed to various factors, including orphan drug legislation, increased disease awareness, biotechnological innovations, global health initiatives, and the rise in personalized medicine.

Key Growth Metrics:

• Market Size (2023): $169.56 billion
• Market Size (2024): $192.22 billion
• CAGR (2023-2024): 13.4%

Future Projections: A Landscape of Promise
The momentum is expected to continue, projecting a market size of $312.46 billion in 2028, at a compound annual growth rate (CAGR) of 12.9%. The forecasted growth is attributed to innovative therapeutic modalities, evolving healthcare reimbursement policies, artificial intelligence and data analytics, expansion of patient registries, and regulatory support for expedited approvals.

Anticipated Growth Metrics:

• Projected Market Size (2028): $312.46 billion
• CAGR (2024-2028): 12.9%

Driving Forces: Personalized Medicine in Rare Disease Treatment

Rising Demand for Personalized Medicine Drives Growth In The Rare Disease Treatment Market

The surge in demand for personalized medicine is a key driver behind the growth of the rare disease treatment market. Personalized medicine tailors medical interventions to an individual’s unique genetic makeup, offering more effective and precise healthcare interventions. In 2022, the FDA’s Center for Drug Evaluation and Research approved 37 new molecular entities (NMEs), with 34% being classified as personalized medicines. This rising demand for personalized medicine is significantly influencing the rare disease treatment market.

Industry Giants Embrace Rare Disease Initiatives

Companies Embrace Rare Disease Initiatives To Gain Competitive Edge

Major players in the rare disease treatment market, including AbbVie, Johnson & Johnson, Novartis, and others, are strategically investing in rare disease initiatives to secure a competitive edge. These initiatives involve coordinated efforts by various stakeholders, such as governments, research institutions, and pharmaceutical companies. For instance, the Oxford-Harrington Rare Disease Centre launched the Therapeutics Accelerator in 2023, aiming to introduce 40 potentially life-changing therapies for rare diseases into clinical trials over the next decade.

View More On The Rare Diseases Treatment Market Report 2024 – https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report

Strategic Acquisitions: AstraZeneca Reinforces Its Position

AstraZeneca Acquires Alexion Pharmaceuticals To Strengthen Rare Disease Portfolio

In July 2021, AstraZeneca made a significant move by acquiring Alexion Pharmaceuticals for $13.3 billion. This strategic acquisition aimed to enhance AstraZeneca’s presence in immunology and leverage Alexion’s innovative research in rare disease drugs. Alexion Pharmaceuticals, a pioneer in researching treatments for rare diseases, became a valuable addition to AstraZeneca’s portfolio.

Market Segmentation: A Comprehensive Approach

The rare diseases treatment market covered in this report is segmented:

1. By Drug Type:
   • Originator Drugs (Patented Molecules)
   • Generic Drugs
2. By Drug Class:
   • Biologics
   • Organic Compounds
3. By Mode Of Administration:
   • Injectable
   • Oral
   • Other Modes Of Administration
4. By Therapeutic Area:
   • Cancer
   • Neurological Conditions
   • Cardiovascular Conditions
   • Musculoskeletal Conditions
   • Hematologic Disorders
   • Infectious Diseases
   • Metabolic Disorders
   • Endocrine Disorders
   • Other Therapeutic Areas
5. By Distribution Channel:
   • Hospital Pharmacies
   • Specialty Pharmacies
   • Retail Pharmacies

North America Leading the Charge

North America was the largest region in the rare disease treatment market in 2023.

The dominance of North America underscores the region’s commitment to addressing rare diseases. The market’s growth is propelled by the region’s robust healthcare infrastructure, advanced research capabilities, and a proactive approach to innovative therapies.

Request A Sample Of The Global Rare Diseases Treatment Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=8248&type=smp